APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nucleoredoxin Antibody

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Nucleoredoxin Antibody Industry Growth and Trends Forecast to 2032

19 December 2025113 pages

Choose your research edition.

Industry ResearchNucleoredoxin Antibody Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Nucleoredoxin Antibody Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Nucleoredoxin Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nucleoredoxin Antibody Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Nucleoredoxin Antibody Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Nucleoredoxin Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Nucleoredoxin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Nucleoredoxin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nucleoredoxin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Nucleoredoxin Antibody include Thermo Fisher Scientific, Merck, United States Biological, Santa Cruz Biotechnology, Proteintech, OriGene Technologies, LSBio, GeneTex and FineTest, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Nucleoredoxin Antibody market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Nucleoredoxin Antibody market size, estimates, and forecasts are presented in terms of sales volume (ml) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Nucleoredoxin Antibody market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Nucleoredoxin Antibody.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Nucleoredoxin Antibody market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Nucleoredoxin Antibody Market by Company

Thermo Fisher Scientific

Merck

United States Biological

Santa Cruz Biotechnology

Proteintech

OriGene Technologies

LSBio

GeneTex

FineTest

CUSABIO

Creative Diagnostics

Creative Biolabs

Bethyl

Abnova

Abcam

Nucleoredoxin Antibody Segment by Type

Polyclonal

Monoclonal

Nucleoredoxin Antibody Segment by Application

Immunofluorescence

Immunoprecipitation

Enzyme Linked Immunosorbent Assay

Western Blot

Others

Nucleoredoxin Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nucleoredoxin Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nucleoredoxin Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nucleoredoxin Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nucleoredoxin Antibody manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Nucleoredoxin Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Polyclonal Table 2. Major Company of Monoclonal Table 3. Global Nucleoredoxin Antibody Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Nucleoredoxin Antibody Sales by Type (2021-2026) & (ml) Table 5. Global Nucleoredoxin Antibody Sales Market Share in Volume by Type (2021-2026) Table 6. Global Nucleoredoxin Antibody Sales by Type (2021-2026) & (US$ Million) Table 7. Global Nucleoredoxin Antibody Sales Market Share in Value by Type (2021-2026) Table 8. Global Nucleoredoxin Antibody Price by Type (2021-2026) & (US$/ml) Table 9. Global Nucleoredoxin Antibody Sales by Type (2027-2032) & (ml) Table 10. Global Nucleoredoxin Antibody Sales Market Share in Volume by Type (2027-2032) Table 11. Global Nucleoredoxin Antibody Sales by Type (2027-2032) & (US$ Million) Table 12. Global Nucleoredoxin Antibody Sales Market Share in Value by Type (2027-2032) Table 13. Global Nucleoredoxin Antibody Price by Type (2027-2032) & (US$/ml) Table 14. North America Nucleoredoxin Antibody Sales by Type (2021-2026) & (ml) Table 15. North America Nucleoredoxin Antibody Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Nucleoredoxin Antibody Sales by Type (2021-2026) & (ml) Table 17. Europe Nucleoredoxin Antibody Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Nucleoredoxin Antibody Sales by Type (2021-2026) & (ml) Table 19. Asia-Pacific Nucleoredoxin Antibody Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Nucleoredoxin Antibody Sales by Type (2021-2026) & (ml) Table 21. Latin America Nucleoredoxin Antibody Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Nucleoredoxin Antibody Sales by Type (2021-2026) & (ml) Table 23. Middle East and Africa Nucleoredoxin Antibody Sales by Type (2021-2026) & (US$ Million) Table 24. Nucleoredoxin Antibody Industry Trends Table 25. Nucleoredoxin Antibody Industry Drivers Table 26. Nucleoredoxin Antibody Industry Opportunities and Challenges Table 27. Nucleoredoxin Antibody Industry Restraints Table 28. Global Nucleoredoxin Antibody Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Nucleoredoxin Antibody Revenue Market Share by Company (2021-2026) Table 30. Global Nucleoredoxin Antibody Sales by Company (2021-2026) & (ml) Table 31. Global Nucleoredoxin Antibody Sales Share by Company (2021-2026) Table 32. Global Nucleoredoxin Antibody Market Price by Company (2021-2026) & (US$/ml) Table 33. Global Nucleoredoxin Antibody Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Nucleoredoxin Antibody Major Company Production Sites and Headquarters Table 35. Global Nucleoredoxin Antibody Company, Product Type & Application Table 36. Global Nucleoredoxin Antibody Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Nucleoredoxin Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Nucleoredoxin Antibody Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Nucleoredoxin Antibody Sales by Region (2021-2026) & (ml) Table 41. Global Nucleoredoxin Antibody Sales Market Share in Volume by Region (2021-2026) Table 42. Global Nucleoredoxin Antibody Sales by Region (2021-2026) & (US$ Million) Table 43. Global Nucleoredoxin Antibody Sales Market Share in Value by Region (2021-2026) Table 44. Global Nucleoredoxin Antibody Sales (ml), Value (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 45. Global Nucleoredoxin Antibody Sales by Region (2027-2032) & (ml) Table 46. Global Nucleoredoxin Antibody Sales Market Share in Volume by Region (2027-2032) Table 47. Global Nucleoredoxin Antibody Sales by Region (2027-2032) & (US$ Million) Table 48. Global Nucleoredoxin Antibody Sales Market Share in Value by Region (2027-2032) Table 49. Global Nucleoredoxin Antibody Sales (ml), Value (US$ Million), Price (US$/ml) and Gross Margin (2027-2032) Table 50. Global Nucleoredoxin Antibody Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Nucleoredoxin Antibody Sales by Application (2021-2026) & (ml) Table 52. Global Nucleoredoxin Antibody Sales Market Share in Volume by Application (2021-2026) Table 53. Global Nucleoredoxin Antibody Sales by Application (2021-2026) & (US$ Million) Table 54. Global Nucleoredoxin Antibody Sales Market Share in Value by Application (2021-2026) Table 55. Global Nucleoredoxin Antibody Price by Application (2021-2026) & (US$/ml) Table 56. Global Nucleoredoxin Antibody Sales by Application (2027-2032) & (ml) Table 57. Global Nucleoredoxin Antibody Sales Market Share in Volume by Application (2027-2032) Table 58. Global Nucleoredoxin Antibody Sales by Application (2027-2032) & (US$ Million) Table 59. Global Nucleoredoxin Antibody Sales Market Share in Value by Application (2027-2032) Table 60. Global Nucleoredoxin Antibody Price by Application (2027-2032) & (US$/ml) Table 61. North America Nucleoredoxin Antibody Sales by Application (2021-2026) & (ml) Table 62. North America Nucleoredoxin Antibody Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Nucleoredoxin Antibody Sales by Application (2021-2026) & (ml) Table 64. Europe Nucleoredoxin Antibody Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Nucleoredoxin Antibody Sales by Application (2021-2026) & (ml) Table 66. Asia-Pacific Nucleoredoxin Antibody Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Nucleoredoxin Antibody Sales by Application (2021-2026) & (ml) Table 68. Latin America Nucleoredoxin Antibody Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Nucleoredoxin Antibody Sales by Application (2021-2026) & (ml) Table 70. Middle East and Africa Nucleoredoxin Antibody Sales by Application (2021-2026) & (US$ Million) Table 71. Thermo Fisher Scientific Company Information Table 72. Thermo Fisher Scientific Business Overview Table 73. Thermo Fisher Scientific Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 74. Thermo Fisher Scientific Nucleoredoxin Antibody Product Portfolio Table 75. Thermo Fisher Scientific Recent Development Table 76. Merck Company Information Table 77. Merck Business Overview Table 78. Merck Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 79. Merck Nucleoredoxin Antibody Product Portfolio Table 80. Merck Recent Development Table 81. United States Biological Company Information Table 82. United States Biological Business Overview Table 83. United States Biological Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 84. United States Biological Nucleoredoxin Antibody Product Portfolio Table 85. United States Biological Recent Development Table 86. Santa Cruz Biotechnology Company Information Table 87. Santa Cruz Biotechnology Business Overview Table 88. Santa Cruz Biotechnology Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 89. Santa Cruz Biotechnology Nucleoredoxin Antibody Product Portfolio Table 90. Santa Cruz Biotechnology Recent Development Table 91. Proteintech Company Information Table 92. Proteintech Business Overview Table 93. Proteintech Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 94. Proteintech Nucleoredoxin Antibody Product Portfolio Table 95. Proteintech Recent Development Table 96. OriGene Technologies Company Information Table 97. OriGene Technologies Business Overview Table 98. OriGene Technologies Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 99. OriGene Technologies Nucleoredoxin Antibody Product Portfolio Table 100. OriGene Technologies Recent Development Table 101. LSBio Company Information Table 102. LSBio Business Overview Table 103. LSBio Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 104. LSBio Nucleoredoxin Antibody Product Portfolio Table 105. LSBio Recent Development Table 106. GeneTex Company Information Table 107. GeneTex Business Overview Table 108. GeneTex Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 109. GeneTex Nucleoredoxin Antibody Product Portfolio Table 110. GeneTex Recent Development Table 111. FineTest Company Information Table 112. FineTest Business Overview Table 113. FineTest Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 114. FineTest Nucleoredoxin Antibody Product Portfolio Table 115. FineTest Recent Development Table 116. CUSABIO Company Information Table 117. CUSABIO Business Overview Table 118. CUSABIO Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 119. CUSABIO Nucleoredoxin Antibody Product Portfolio Table 120. CUSABIO Recent Development Table 121. Creative Diagnostics Company Information Table 122. Creative Diagnostics Business Overview Table 123. Creative Diagnostics Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 124. Creative Diagnostics Nucleoredoxin Antibody Product Portfolio Table 125. Creative Diagnostics Recent Development Table 126. Creative Biolabs Company Information Table 127. Creative Biolabs Business Overview Table 128. Creative Biolabs Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 129. Creative Biolabs Nucleoredoxin Antibody Product Portfolio Table 130. Creative Biolabs Recent Development Table 131. Bethyl Company Information Table 132. Bethyl Business Overview Table 133. Bethyl Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 134. Bethyl Nucleoredoxin Antibody Product Portfolio Table 135. Bethyl Recent Development Table 136. Abnova Company Information Table 137. Abnova Business Overview Table 138. Abnova Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 139. Abnova Nucleoredoxin Antibody Product Portfolio Table 140. Abnova Recent Development Table 141. Abcam Company Information Table 142. Abcam Business Overview Table 143. Abcam Nucleoredoxin Antibody Sales (ml), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 144. Abcam Nucleoredoxin Antibody Product Portfolio Table 145. Abcam Recent Development Table 146. North America Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country (ml): 2021 VS 2025 VS 2032 Table 147. North America Nucleoredoxin Antibody Sales by Country (2021-2026) & (ml) Table 148. North America Nucleoredoxin Antibody Sales Market Share by Country (2021-2026) Table 149. North America Nucleoredoxin Antibody Sales Forecast by Country (2027-2032) & (ml) Table 150. North America Nucleoredoxin Antibody Sales Market Share Forecast by Country (2027-2032) Table 151. North America Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. North America Nucleoredoxin Antibody Market Size by Country (2021-2026) & (US$ Million) Table 153. North America Nucleoredoxin Antibody Market Share by Country (2021-2026) Table 154. North America Nucleoredoxin Antibody Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. North America Nucleoredoxin Antibody Market Share Forecast by Country (2027-2032) Table 156. Europe Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country (ml): 2021 VS 2025 VS 2032 Table 157. Europe Nucleoredoxin Antibody Sales by Country (2021-2026) & (ml) Table 158. Europe Nucleoredoxin Antibody Sales Market Share by Country (2021-2026) Table 159. Europe Nucleoredoxin Antibody Sales Forecast by Country (2027-2032) & (ml) Table 160. Europe Nucleoredoxin Antibody Sales Market Share Forecast by Country (2027-2032) Table 161. Europe Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Europe Nucleoredoxin Antibody Market Size by Country (2021-2026) & (US$ Million) Table 163. Europe Nucleoredoxin Antibody Market Share by Country (2021-2026) Table 164. Europe Nucleoredoxin Antibody Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Europe Nucleoredoxin Antibody Market Share Forecast by Country (2027-2032) Table 166. Asia-Pacific Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country (ml): 2021 VS 2025 VS 2032 Table 167. Asia-Pacific Nucleoredoxin Antibody Sales by Country (2021-2026) & (ml) Table 168. Asia-Pacific Nucleoredoxin Antibody Sales Market Share by Country (2021-2026) Table 169. Asia-Pacific Nucleoredoxin Antibody Sales Forecast by Country (2027-2032) & (ml) Table 170. Asia-Pacific Nucleoredoxin Antibody Sales Market Share Forecast by Country (2027-2032) Table 171. Asia-Pacific Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Asia-Pacific Nucleoredoxin Antibody Market Size by Country (2021-2026) & (US$ Million) Table 173. Asia-Pacific Nucleoredoxin Antibody Market Share by Country (2021-2026) Table 174. Asia-Pacific Nucleoredoxin Antibody Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Asia-Pacific Nucleoredoxin Antibody Market Share Forecast by Country (2027-2032) Table 176. Latin America Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country (ml): 2021 VS 2025 VS 2032 Table 177. Latin America Nucleoredoxin Antibody Sales by Country (2021-2026) & (ml) Table 178. Latin America Nucleoredoxin Antibody Sales Market Share by Country (2021-2026) Table 179. Latin America Nucleoredoxin Antibody Sales Forecast by Country (2027-2032) & (ml) Table 180. Latin America Nucleoredoxin Antibody Sales Market Share Forecast by Country (2027-2032) Table 181. Latin America Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Latin America Nucleoredoxin Antibody Market Size by Country (2021-2026) & (US$ Million) Table 183. Latin America Nucleoredoxin Antibody Market Share by Country (2021-2026) Table 184. Latin America Nucleoredoxin Antibody Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Latin America Nucleoredoxin Antibody Market Share Forecast by Country (2027-2032) Table 186. Middle East and Africa Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country (ml): 2021 VS 2025 VS 2032 Table 187. Middle East and Africa Nucleoredoxin Antibody Sales by Country (2021-2026) & (ml) Table 188. Middle East and Africa Nucleoredoxin Antibody Sales Market Share by Country (2021-2026) Table 189. Middle East and Africa Nucleoredoxin Antibody Sales Forecast by Country (2027-2032) & (ml) Table 190. Middle East and Africa Nucleoredoxin Antibody Sales Market Share Forecast by Country (2027-2032) Table 191. Middle East and Africa Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 192. Middle East and Africa Nucleoredoxin Antibody Market Size by Country (2021-2026) & (US$ Million) Table 193. Middle East and Africa Nucleoredoxin Antibody Market Share by Country (2021-2026) Table 194. Middle East and Africa Nucleoredoxin Antibody Market Size Forecast by Country (2027-2032) & (US$ Million) Table 195. Middle East and Africa Nucleoredoxin Antibody Market Share Forecast by Country (2027-2032) Table 196. Key Raw Materials Table 197. Raw Materials Key Suppliers Table 198. Nucleoredoxin Antibody Distributors List Table 199. Nucleoredoxin Antibody Customers List Table 200. Research Programs/Design for This Report Table 201. Authors List of This Report Table 202. Secondary Sources Table 203. Primary Sources List of Figures Figure 1. Nucleoredoxin Antibody Image Figure 2. Global Nucleoredoxin Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nucleoredoxin Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global Nucleoredoxin Antibody Sales (2021-2032) & (ml) Figure 5. Polyclonal Image Figure 6. Global Polyclonal Sales YoY Growth (2021-2032) & (ml) Figure 7. Monoclonal Image Figure 8. Global Monoclonal Sales YoY Growth (2021-2032) & (ml) Figure 9. Global Nucleoredoxin Antibody Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Nucleoredoxin Antibody Market Share by Type 2025 VS 2032 Figure 11. North America Nucleoredoxin Antibody Sales Market Share in Volume by Type in 2025 Figure 12. North America Nucleoredoxin Antibody Sales Market Share in Value by Type in 2025 Figure 13. Europe Nucleoredoxin Antibody Sales Market Share in Volume by Type in 2025 Figure 14. Europe Nucleoredoxin Antibody Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Nucleoredoxin Antibody Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Nucleoredoxin Antibody Sales Market Share in Value by Type in 2025 Figure 17. Latin America Nucleoredoxin Antibody Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Nucleoredoxin Antibody Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Nucleoredoxin Antibody Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Nucleoredoxin Antibody Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Nucleoredoxin Antibody Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Immunofluorescence Image Figure 24. Global Immunofluorescence Sales YoY Growth (2021-2032) & (ml) Figure 25. Immunoprecipitation Image Figure 26. Global Immunoprecipitation Sales YoY Growth (2021-2032) & (ml) Figure 27. Enzyme Linked Immunosorbent Assay Image Figure 28. Global Enzyme Linked Immunosorbent Assay Sales YoY Growth (2021-2032) & (ml) Figure 29. Western Blot Image Figure 30. Global Western Blot Sales YoY Growth (2021-2032) & (ml) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (ml) Figure 33. Global Nucleoredoxin Antibody Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Nucleoredoxin Antibody Market Share by Application 2025 VS 2032 Figure 35. North America Nucleoredoxin Antibody Sales Market Share in Volume by Application in 2025 Figure 36. North America Nucleoredoxin Antibody Sales Market Share in Value by Application in 2025 Figure 37. Europe Nucleoredoxin Antibody Sales Market Share in Volume by Application in 2025 Figure 38. Europe Nucleoredoxin Antibody Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Nucleoredoxin Antibody Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Nucleoredoxin Antibody Sales Market Share in Value by Application in 2025 Figure 41. Latin America Nucleoredoxin Antibody Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Nucleoredoxin Antibody Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Nucleoredoxin Antibody Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Nucleoredoxin Antibody Sales Market Share in Value by Application in 2025 Figure 45. North America Nucleoredoxin Antibody Sales by Country: 2021 VS 2025 VS 2032 (ml) Figure 46. North America Nucleoredoxin Antibody Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Nucleoredoxin Antibody Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Nucleoredoxin Antibody Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Nucleoredoxin Antibody Sales by Country: 2021 VS 2025 VS 2032 (ml) Figure 50. Europe Nucleoredoxin Antibody Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Nucleoredoxin Antibody Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Nucleoredoxin Antibody Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Nucleoredoxin Antibody Sales by Country: 2021 VS 2025 VS 2032 (ml) Figure 54. Asia-Pacific Nucleoredoxin Antibody Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Nucleoredoxin Antibody Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Nucleoredoxin Antibody Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Nucleoredoxin Antibody Sales by Country: 2021 VS 2025 VS 2032 (ml) Figure 58. Latin America Nucleoredoxin Antibody Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Nucleoredoxin Antibody Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Nucleoredoxin Antibody Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Nucleoredoxin Antibody Sales by Country: 2021 VS 2025 VS 2032 (ml) Figure 62. Middle East and Africa Nucleoredoxin Antibody Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Nucleoredoxin Antibody Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Nucleoredoxin Antibody Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Nucleoredoxin Antibody Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Nucleoredoxin Antibody Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunofluorescence
  • Immunoprecipitation
  • Enzyme Linked Immunosorbent Assay
  • Western Blot
  • Others
Companies covered
  • Thermo Fisher Scientific
  • Merck
  • United States Biological
  • Santa Cruz Biotechnology
  • Proteintech
  • OriGene Technologies
  • LSBio
  • GeneTex
  • FineTest
  • CUSABIO
  • Creative Diagnostics
  • Creative Biolabs
  • Bethyl
  • Abnova
  • Abcam

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Nucleoredoxin Antibody Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Nucleoredoxin Antibody Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Nucleoredoxin Antibody Market by Type
  6. 1.3.1 Polyclonal
  7. 1.3.2 Monoclonal
  8. 1.4 Global Nucleoredoxin Antibody Market Size by Type
  9. 1.4.1 Global Nucleoredoxin Antibody Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Nucleoredoxin Antibody Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Nucleoredoxin Antibody Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Nucleoredoxin Antibody Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Nucleoredoxin Antibody Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Nucleoredoxin Antibody Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Nucleoredoxin Antibody Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Nucleoredoxin Antibody Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Nucleoredoxin Antibody Industry Trends
  2. 2.2 Nucleoredoxin Antibody Industry Drivers
  3. 2.3 Nucleoredoxin Antibody Industry Opportunities and Challenges
  4. 2.4 Nucleoredoxin Antibody Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Nucleoredoxin Antibody Revenue (2021-2026)
  2. 3.2 Global Top Players by Nucleoredoxin Antibody Sales (2021-2026)
  3. 3.3 Global Top Players by Nucleoredoxin Antibody Price (2021-2026)
  4. 3.4 Global Nucleoredoxin Antibody Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Nucleoredoxin Antibody Major Company Production Sites & Headquarters
  6. 3.6 Global Nucleoredoxin Antibody Company, Product Type & Application
  7. 3.7 Global Nucleoredoxin Antibody Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Nucleoredoxin Antibody Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Nucleoredoxin Antibody Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Nucleoredoxin Antibody Tier 1, Tier 2, and Tier 3
4 Nucleoredoxin Antibody Regional Status and Outlook
  1. 4.1 Global Nucleoredoxin Antibody Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Nucleoredoxin Antibody Historic Market Size by Region
  3. 4.2.1 Global Nucleoredoxin Antibody Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Nucleoredoxin Antibody Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Nucleoredoxin Antibody Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Nucleoredoxin Antibody Forecasted Market Size by Region
  7. 4.3.1 Global Nucleoredoxin Antibody Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Nucleoredoxin Antibody Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Nucleoredoxin Antibody Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Nucleoredoxin Antibody by Application
  1. 5.1 Nucleoredoxin Antibody Market by Application
  2. 5.1.1 Immunofluorescence
  3. 5.1.2 Immunoprecipitation
  4. 5.1.3 Enzyme Linked Immunosorbent Assay
  5. 5.1.4 Western Blot
  6. 5.1.5 Others
  7. 5.2 Global Nucleoredoxin Antibody Market Size by Application
  8. 5.2.1 Global Nucleoredoxin Antibody Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Nucleoredoxin Antibody Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Nucleoredoxin Antibody Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Nucleoredoxin Antibody Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Nucleoredoxin Antibody Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Nucleoredoxin Antibody Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Nucleoredoxin Antibody Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Nucleoredoxin Antibody Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Thermo Fisher Scientific
  2. 6.1.1 Thermo Fisher Scientific Company Information
  3. 6.1.2 Thermo Fisher Scientific Business Overview
  4. 6.1.3 Thermo Fisher Scientific Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Thermo Fisher Scientific Nucleoredoxin Antibody Product Portfolio
  6. 6.1.5 Thermo Fisher Scientific Recent Developments
  7. 6.2 Merck
  8. 6.2.1 Merck Company Information
  9. 6.2.2 Merck Business Overview
  10. 6.2.3 Merck Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Merck Nucleoredoxin Antibody Product Portfolio
  12. 6.2.5 Merck Recent Developments
  13. 6.3 United States Biological
  14. 6.3.1 United States Biological Company Information
  15. 6.3.2 United States Biological Business Overview
  16. 6.3.3 United States Biological Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 United States Biological Nucleoredoxin Antibody Product Portfolio
  18. 6.3.5 United States Biological Recent Developments
  19. 6.4 Santa Cruz Biotechnology
  20. 6.4.1 Santa Cruz Biotechnology Company Information
  21. 6.4.2 Santa Cruz Biotechnology Business Overview
  22. 6.4.3 Santa Cruz Biotechnology Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Santa Cruz Biotechnology Nucleoredoxin Antibody Product Portfolio
  24. 6.4.5 Santa Cruz Biotechnology Recent Developments
  25. 6.5 Proteintech
  26. 6.5.1 Proteintech Company Information
  27. 6.5.2 Proteintech Business Overview
  28. 6.5.3 Proteintech Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Proteintech Nucleoredoxin Antibody Product Portfolio
  30. 6.5.5 Proteintech Recent Developments
  31. 6.6 OriGene Technologies
  32. 6.6.1 OriGene Technologies Company Information
  33. 6.6.2 OriGene Technologies Business Overview
  34. 6.6.3 OriGene Technologies Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 OriGene Technologies Nucleoredoxin Antibody Product Portfolio
  36. 6.6.5 OriGene Technologies Recent Developments
  37. 6.7 LSBio
  38. 6.7.1 LSBio Company Information
  39. 6.7.2 LSBio Business Overview
  40. 6.7.3 LSBio Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 LSBio Nucleoredoxin Antibody Product Portfolio
  42. 6.7.5 LSBio Recent Developments
  43. 6.8 GeneTex
  44. 6.8.1 GeneTex Company Information
  45. 6.8.2 GeneTex Business Overview
  46. 6.8.3 GeneTex Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 GeneTex Nucleoredoxin Antibody Product Portfolio
  48. 6.8.5 GeneTex Recent Developments
  49. 6.9 FineTest
  50. 6.9.1 FineTest Company Information
  51. 6.9.2 FineTest Business Overview
  52. 6.9.3 FineTest Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 FineTest Nucleoredoxin Antibody Product Portfolio
  54. 6.9.5 FineTest Recent Developments
  55. 6.10 CUSABIO
  56. 6.10.1 CUSABIO Company Information
  57. 6.10.2 CUSABIO Business Overview
  58. 6.10.3 CUSABIO Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 CUSABIO Nucleoredoxin Antibody Product Portfolio
  60. 6.10.5 CUSABIO Recent Developments
  61. 6.11 Creative Diagnostics
  62. 6.11.1 Creative Diagnostics Company Information
  63. 6.11.2 Creative Diagnostics Business Overview
  64. 6.11.3 Creative Diagnostics Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Creative Diagnostics Nucleoredoxin Antibody Product Portfolio
  66. 6.11.5 Creative Diagnostics Recent Developments
  67. 6.12 Creative Biolabs
  68. 6.12.1 Creative Biolabs Company Information
  69. 6.12.2 Creative Biolabs Business Overview
  70. 6.12.3 Creative Biolabs Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Creative Biolabs Nucleoredoxin Antibody Product Portfolio
  72. 6.12.5 Creative Biolabs Recent Developments
  73. 6.13 Bethyl
  74. 6.13.1 Bethyl Company Information
  75. 6.13.2 Bethyl Business Overview
  76. 6.13.3 Bethyl Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Bethyl Nucleoredoxin Antibody Product Portfolio
  78. 6.13.5 Bethyl Recent Developments
  79. 6.14 Abnova
  80. 6.14.1 Abnova Company Information
  81. 6.14.2 Abnova Business Overview
  82. 6.14.3 Abnova Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Abnova Nucleoredoxin Antibody Product Portfolio
  84. 6.14.5 Abnova Recent Developments
  85. 6.15 Abcam
  86. 6.15.1 Abcam Company Information
  87. 6.15.2 Abcam Business Overview
  88. 6.15.3 Abcam Nucleoredoxin Antibody Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Abcam Nucleoredoxin Antibody Product Portfolio
  90. 6.15.5 Abcam Recent Developments
7 North America by Country
  1. 7.1 North America Nucleoredoxin Antibody Sales by Country
  2. 7.1.1 North America Nucleoredoxin Antibody Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Nucleoredoxin Antibody Sales by Country (2021-2026)
  4. 7.1.3 North America Nucleoredoxin Antibody Sales Forecast by Country (2027-2032)
  5. 7.2 North America Nucleoredoxin Antibody Market Size by Country
  6. 7.2.1 North America Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Nucleoredoxin Antibody Market Size by Country (2021-2026)
  8. 7.2.3 North America Nucleoredoxin Antibody Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Nucleoredoxin Antibody Sales by Country
  2. 8.1.1 Europe Nucleoredoxin Antibody Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Nucleoredoxin Antibody Sales by Country (2021-2026)
  4. 8.1.3 Europe Nucleoredoxin Antibody Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Nucleoredoxin Antibody Market Size by Country
  6. 8.2.1 Europe Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Nucleoredoxin Antibody Market Size by Country (2021-2026)
  8. 8.2.3 Europe Nucleoredoxin Antibody Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Nucleoredoxin Antibody Sales by Country
  2. 9.1.1 Asia-Pacific Nucleoredoxin Antibody Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Nucleoredoxin Antibody Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Nucleoredoxin Antibody Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Nucleoredoxin Antibody Market Size by Country
  6. 9.2.1 Asia-Pacific Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Nucleoredoxin Antibody Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Nucleoredoxin Antibody Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Nucleoredoxin Antibody Sales by Country
  2. 10.1.1 South America Nucleoredoxin Antibody Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Nucleoredoxin Antibody Sales by Country (2021-2026)
  4. 10.1.3 South America Nucleoredoxin Antibody Sales Forecast by Country (2027-2032)
  5. 10.2 South America Nucleoredoxin Antibody Market Size by Country
  6. 10.2.1 South America Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Nucleoredoxin Antibody Market Size by Country (2021-2026)
  8. 10.2.3 South America Nucleoredoxin Antibody Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Nucleoredoxin Antibody Sales by Country
  2. 11.1.1 Middle East and Africa Nucleoredoxin Antibody Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Nucleoredoxin Antibody Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Nucleoredoxin Antibody Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Nucleoredoxin Antibody Market Size by Country
  6. 11.2.1 Middle East and Africa Nucleoredoxin Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Nucleoredoxin Antibody Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Nucleoredoxin Antibody Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Nucleoredoxin Antibody Value Chain Analysis
  2. 12.1.1 Nucleoredoxin Antibody Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Nucleoredoxin Antibody Production Mode & Process
  7. 12.2 Nucleoredoxin Antibody Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Nucleoredoxin Antibody Distributors
  10. 12.2.3 Nucleoredoxin Antibody Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst